ADAM9 and familial pancreatic carcinoma: Hence, our systematic analysis not only proposed amplification of ADAM9 which could be utilized as a biomarker for PDAC metastasis, but also offered support for the utilization of SRC inhibitor (Bosutinib) in the treatment of pancreatic cancer.